Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Largest borrow rate increases among liquid names » 08:45
07/02/20
07/02
08:45
07/02/20
08:45
MARK

Remark Holdings

$2.30 /

-0.05 (-2.13%)

, APT

Alpha Pro Tech

$17.70 /

-0.05 (-0.28%)

, AMC

AMC Entertainment

$4.56 /

+0.275 (+6.42%)

, BCLI

BrainStorm

$11.21 /

+0.01 (+0.09%)

, BGS

B&G Foods

$24.18 /

-0.23 (-0.94%)

, YCBD

cbdMD

$1.88 /

-0.005 (-0.27%)

, TTNP

Titan Pharmaceuticals

$0.30 /

-0.0085 (-2.80%)

, PEI

Pennsylvania REIT

$1.39 /

+0.03 (+2.21%)

, CRC

California Resources

$1.27 /

+0.045 (+3.69%)

, GRPN

Groupon

$17.50 /

-0.59 (-3.26%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Remark Media (MARK) 190.24% +3.93, Alpha Pro Tech (APT) 57.24% +2.22, AMC Entertainment (AMC) 71.31% +1.92, BrainStorm (BCLI) 70.30% +1.90, B&G Foods (BGS) 12.82% +1.82, cbdMD (YCBD) 24.11% +1.24, Titan Pharmaceuticals (TTNP) 37.01% +0.62, Pennsylvania REIT (PEI) 86.36% +0.49, California Resources (CRC) 270.47% +0.37, and Groupon (GRPN) 0.68% +0.33.

ShowHide Related Items >><<
YCBD cbdMD
$1.88 /

-0.005 (-0.27%)

TTNP Titan Pharmaceuticals
$0.30 /

-0.0085 (-2.80%)

PEI Pennsylvania REIT
$1.39 /

+0.03 (+2.21%)

MARK Remark Holdings
$2.30 /

-0.05 (-2.13%)

GRPN Groupon
$17.50 /

-0.59 (-3.26%)

CRC California Resources
$1.27 /

+0.045 (+3.69%)

BGS B&G Foods
$24.18 /

-0.23 (-0.94%)

BCLI BrainStorm
$11.21 /

+0.01 (+0.09%)

APT Alpha Pro Tech
$17.70 /

-0.05 (-0.28%)

AMC AMC Entertainment
$4.56 /

+0.275 (+6.42%)

MARK Remark Holdings
$2.30 /

-0.05 (-2.13%)

06/10/20 Roth Capital
Roth checks point to Kent Services as Remark Holdings distribution partner
05/27/20 Roth Capital
Wynn video 'clearly shows' Remark AI technology in use, says Roth Capital
07/15/19 Roth Capital
Sharecare liquidity event would help capitalize Remark AI business, says Roth Capital
APT Alpha Pro Tech
$17.70 /

-0.05 (-0.28%)

AMC AMC Entertainment
$4.56 /

+0.275 (+6.42%)

06/30/20 Imperial Capital
AMC Entertainment price target lowered to $4 from $6 at Imperial Capital
06/29/20 Credit Suisse
Cinemark downgraded to Neutral from Outperform at Credit Suisse
06/29/20 Credit Suisse
AMC Entertainment downgraded to Underperform from Neutral at Credit Suisse
06/17/20 Citi
AMC Entertainment price target raised to $4 from $1 at Citi
BCLI BrainStorm
$11.21 /

+0.01 (+0.09%)

BGS B&G Foods
$24.18 /

-0.23 (-0.94%)

06/12/20
Fly Intel: Top five analyst initiations
06/11/20 DA Davidson
B&G Foods initiated with a Neutral at DA Davidson
06/11/20 RBC Capital
B&G Foods initiated with a Sector Perform at RBC Capital
05/13/20
Fly Intel: Top five analyst upgrades
YCBD cbdMD
$1.88 /

-0.005 (-0.27%)

03/09/20 Cantor Fitzgerald
cbdMD price target lowered to $1.20 from $3.40 at Cantor Fitzgerald
11/07/19 Cantor Fitzgerald
Cantor Fitzgerald expects industry consolidation in consumer CBD wellness trend
11/07/19 Cantor Fitzgerald
cbdMD initiated with a Neutral at Cantor Fitzgerald
09/10/19 Benchmark
cbdMD initiated with a Speculative Buy at Benchmark
TTNP Titan Pharmaceuticals
$0.30 /

-0.0085 (-2.80%)

10/23/19 Maxim
Titan Pharmaceuticals upgraded to Buy from Hold at Maxim
10/23/19 Maxim
Titan Pharmaceuticals upgraded to Buy from Hold at Maxim
08/16/19
Titan Pharmaceuticals downgraded to Hold from Buy at Maxim
08/15/19 Maxim
Titan Pharmaceuticals downgraded to Hold from Buy at Maxim
PEI Pennsylvania REIT
$1.39 /

+0.03 (+2.21%)

03/26/20 RBC Capital
Cheesecake, AMC news highlight tenants financial stress, says RBC Capital
01/16/20 SunTrust
Pennsylvania REIT downgraded to Sell from Hold at SunTrust
01/15/20 SunTrust
Pennsylvania REIT downgraded to Sell from Hold at SunTrust
09/23/19 Citi
Pennsylvania REIT downgraded to Sell from Neutral at Citi
CRC California Resources
$1.27 /

+0.045 (+3.69%)

03/25/20 Imperial Capital
California Resources downgraded to In-Line from Outperform at Imperial Capital
03/17/20 Raymond James
California Resources downgraded to Market Perform from Outperform at Raymond James
03/17/20 Raymond James
California Resources downgraded to Market Perform from Outperform at Raymond James
03/09/20 BofA
California Resources downgraded to Underperform from Neutral at BofA
GRPN Groupon
$17.50 /

-0.59 (-3.26%)

06/18/20 Wedbush
Groupon price target lowered to $22 from $35 at Wedbush
06/18/20 Barclays
Groupon business model remains uncertain, says Barclays
06/17/20 DA Davidson
Groupon price target raised to $32 from $23 at DA Davidson
02/25/20 Ascendiant
Groupon price target lowered to $1.75 from $3.25 at Ascendiant
YCBD cbdMD
$1.88 /

-0.005 (-0.27%)

TTNP Titan Pharmaceuticals
$0.30 /

-0.0085 (-2.80%)

PEI Pennsylvania REIT
$1.39 /

+0.03 (+2.21%)

GRPN Groupon
$17.50 /

-0.59 (-3.26%)

CRC California Resources
$1.27 /

+0.045 (+3.69%)

BGS B&G Foods
$24.18 /

-0.23 (-0.94%)

BCLI BrainStorm
$11.21 /

+0.01 (+0.09%)

APT Alpha Pro Tech
$17.70 /

-0.05 (-0.28%)

AMC AMC Entertainment
$4.56 /

+0.275 (+6.42%)

  • 10
    Jan
GRPN Groupon
$17.50 /

-0.59 (-3.26%)

CRC California Resources
$1.27 /

+0.045 (+3.69%)

APT Alpha Pro Tech
$17.70 /

-0.05 (-0.28%)

AMC AMC Entertainment
$4.56 /

+0.275 (+6.42%)

PEI Pennsylvania REIT
$1.39 /

+0.03 (+2.21%)

MARK Remark Holdings
$2.30 /

-0.05 (-2.13%)

GRPN Groupon
$17.50 /

-0.59 (-3.26%)

CRC California Resources
$1.27 /

+0.045 (+3.69%)

BGS B&G Foods
$24.18 /

-0.23 (-0.94%)

APT Alpha Pro Tech
$17.70 /

-0.05 (-0.28%)

AMC AMC Entertainment
$4.56 /

+0.275 (+6.42%)

TTNP Titan Pharmaceuticals
$0.30 /

-0.0085 (-2.80%)

PEI Pennsylvania REIT
$1.39 /

+0.03 (+2.21%)

MARK Remark Holdings
$2.30 /

-0.05 (-2.13%)

GRPN Groupon
$17.50 /

-0.59 (-3.26%)

CRC California Resources
$1.27 /

+0.045 (+3.69%)

BGS B&G Foods
$24.18 /

-0.23 (-0.94%)

BCLI BrainStorm
$11.21 /

+0.01 (+0.09%)

APT Alpha Pro Tech
$17.70 /

-0.05 (-0.28%)

AMC AMC Entertainment
$4.56 /

+0.275 (+6.42%)

Hot Stocks
BrainStorm completes all dosing in Phase 3 pivotal trial of NurOwn in ALS » 06:51
07/02/20
07/02
06:51
07/02/20
06:51
BCLI

BrainStorm

$11.21 /

+0.01 (+0.09%)

BrainStorm announced that…

BrainStorm announced that final participant dosing has been administered in the Phase 3 pivotal trial of NurOwn in amyotrophic lateral sclerosis, or ALS. BrainStorm said in a release, "The trial enrolled approximately 200 participants, randomized 1:1 to receive three doses of MSC-NTF cells or placebo, administered over four months. As previously reported, the Company expects top-line data from the trial to be available in the fourth quarter of 2020, consistent with the timeline established upon trial enrollment."

ShowHide Related Items >><<
BCLI BrainStorm
$11.21 /

+0.01 (+0.09%)

BCLI BrainStorm
$11.21 /

+0.01 (+0.09%)

BCLI BrainStorm
$11.21 /

+0.01 (+0.09%)

Wednesday
Conference/Events
BrainStorm to hold a KOL conference call » 16:31
07/01/20
07/01
16:31
07/01/20
16:31
BCLI

BrainStorm

$11.21 /

+0.01 (+0.09%)

Management holds a Key…

Management holds a Key Opinion Leader conference call to discuss the Company's Alzheimer's Disease Clinical Program on July 8 at 8:15 am. Webcast Link

ShowHide Related Items >><<
BCLI BrainStorm
$11.21 /

+0.01 (+0.09%)

BCLI BrainStorm
$11.21 /

+0.01 (+0.09%)

BCLI BrainStorm
$11.21 /

+0.01 (+0.09%)

Options
Largest borrow rate increases among liquid names » 08:45
07/01/20
07/01
08:45
07/01/20
08:45
FCEL

FuelCell

$2.26 /

-0.07 (-3.00%)

, VAL

Valaris

$0.65 /

-0.0538 (-7.60%)

, BGS

B&G Foods

$24.41 /

-0.045 (-0.18%)

, BCLI

BrainStorm

$11.20 /

+0.145 (+1.31%)

, CBL

CBL & Associates

$0.27 /

-0.0048 (-1.74%)

, WPG

Washington Prime

$0.84 /

+ (+0.00%)

, SLNO

Soleno Therapeutics

$2.21 /

+0.13 (+6.25%)

, SKT

Tanger Factory

$7.13 /

-0.17 (-2.33%)

, MAC

Macerich

$8.97 /

+0.195 (+2.22%)

, LAKE

Lakeland Industries

$22.38 /

+0.54 (+2.47%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: FuelCell (FCEL) 42.70% +5.69, Valaris Plc (VAL) 123.49% +4.11, B&G Foods (BGS) 34.71% +4.05, BrainStorm (BCLI) 41.08% +2.31, CBL & Associates (CBL) 19.67% +2.18, Washington Prime (WPG) 64.65% +1.65, Soleno Therapeutics (SLNO) 4.04% +1.60, Tanger Factory (SKT) 17.78% +1.54, Macerich (MAC) 14.59% +1.54, and Lakeland Industries (LAKE) 21.94% +1.20.

ShowHide Related Items >><<
WPG Washington Prime
$0.84 /

+ (+0.00%)

VAL Valaris
$0.65 /

-0.0538 (-7.60%)

SLNO Soleno Therapeutics
$2.21 /

+0.13 (+6.25%)

SKT Tanger Factory
$7.13 /

-0.17 (-2.33%)

MAC Macerich
$8.97 /

+0.195 (+2.22%)

LAKE Lakeland Industries
$22.38 /

+0.54 (+2.47%)

FCEL FuelCell
$2.26 /

-0.07 (-3.00%)

CBL CBL & Associates
$0.27 /

-0.0048 (-1.74%)

BGS B&G Foods
$24.41 /

-0.045 (-0.18%)

BCLI BrainStorm
$11.20 /

+0.145 (+1.31%)

FCEL FuelCell
$2.26 /

-0.07 (-3.00%)

06/15/20
Fly Intel: Top five analyst downgrades
06/15/20 Craig-Hallum
FuelCell downgraded to Sell at Craig-Hallum
06/12/20 Craig-Hallum
FuelCell downgraded to Sell from Hold at Craig-Hallum
03/16/20 Craig-Hallum
FuelCell upgraded to Hold at Craig-Hallum
VAL Valaris
$0.65 /

-0.0538 (-7.60%)

05/13/20 Credit Suisse
Valaris downgraded to Underperform from Neutral at Credit Suisse
04/21/20 RBC Capital
Valaris downgraded to Underperform from Sector Perform at RBC Capital
04/21/20 RBC Capital
Valaris downgraded to Underperform from Sector Perform at RBC Capital
03/20/20 Credit Suisse
Valaris downgraded to Neutral from Outperform at Credit Suisse
BGS B&G Foods
$24.41 /

-0.045 (-0.18%)

06/12/20
Fly Intel: Top five analyst initiations
06/11/20 DA Davidson
B&G Foods initiated with a Neutral at DA Davidson
06/11/20 RBC Capital
B&G Foods initiated with a Sector Perform at RBC Capital
05/13/20
Fly Intel: Top five analyst upgrades
BCLI BrainStorm
$11.20 /

+0.145 (+1.31%)

CBL CBL & Associates
$0.27 /

-0.0048 (-1.74%)

03/26/20 RBC Capital
Cheesecake, AMC news highlight tenants financial stress, says RBC Capital
12/03/19 Stifel
Stifel says CBL Properties dividend suspension likely surprise to some investors
WPG Washington Prime
$0.84 /

+ (+0.00%)

06/04/20 Compass Point
Compass Point starts Washington Prime with Neutral, $1 price target
06/04/20 Compass Point
Washington Prime initiated with a Neutral at Compass Point
SLNO Soleno Therapeutics
$2.21 /

+0.13 (+6.25%)

04/07/20 Craig-Hallum
Millendo failure in PWS doesn't add risk to Soleno readout, says Craig-Hallum
01/10/20 Craig-Hallum
Soleno Therapeutics initiated with a Buy, $8 price target at Craig-Hallum
01/10/20 Craig-Hallum
Soleno Therapeutics initiated with a Buy at Craig-Hallum
12/23/19 Laidlaw
Soleno Therapeutics resumed with a Buy at Laidlaw
SKT Tanger Factory
$7.13 /

-0.17 (-2.33%)

07/01/20 Goldman Sachs
Tanger Factory resumed with a Neutral at Goldman Sachs
06/18/20 JPMorgan
Tanger Factory price target lowered to $8 from $15 at JPMorgan
06/04/20 Compass Point
Compass Point starts Tanger Factory at Sell citing risk from bankruptcies
06/04/20 Compass Point
Tanger Factory initiated with a Sell at Compass Point
MAC Macerich
$8.97 /

+0.195 (+2.22%)

07/01/20 Goldman Sachs
Macerich resumed with a Sell at Goldman Sachs
06/18/20 JPMorgan
Macerich price target lowered to $11 from $30 at JPMorgan
06/15/20 Evercore ISI
Macerich downgraded to Underperform from In Line at Evercore ISI
06/04/20 Compass Point
Compass Point starts Macerich with Neutral, $9 price target
LAKE Lakeland Industries
$22.38 /

+0.54 (+2.47%)

06/10/20 Roth Capital
Lakeland Industries price target raised to $24 from $18.50 at Roth Capital
06/10/20 Craig-Hallum
Lakeland Industries price target raised to $30 from $22 at Craig-Hallum
06/10/20 Benchmark
Lakeland Industries price target raised to $31 after 'blow-out' at Benchmark
06/09/20 Benchmark
Benchmark starts PPE maker Lakeland Industries at Buy
VAL Valaris
$0.65 /

-0.0538 (-7.60%)

SLNO Soleno Therapeutics
$2.21 /

+0.13 (+6.25%)

SKT Tanger Factory
$7.13 /

-0.17 (-2.33%)

MAC Macerich
$8.97 /

+0.195 (+2.22%)

LAKE Lakeland Industries
$22.38 /

+0.54 (+2.47%)

FCEL FuelCell
$2.26 /

-0.07 (-3.00%)

CBL CBL & Associates
$0.27 /

-0.0048 (-1.74%)

BGS B&G Foods
$24.41 /

-0.045 (-0.18%)

BCLI BrainStorm
$11.20 /

+0.145 (+1.31%)

  • 24
    Jun
  • 23
    Oct
VAL Valaris
$0.65 /

-0.0538 (-7.60%)

LAKE Lakeland Industries
$22.38 /

+0.54 (+2.47%)

VAL Valaris
$0.65 /

-0.0538 (-7.60%)

SLNO Soleno Therapeutics
$2.21 /

+0.13 (+6.25%)

LAKE Lakeland Industries
$22.38 /

+0.54 (+2.47%)

FCEL FuelCell
$2.26 /

-0.07 (-3.00%)

BGS B&G Foods
$24.41 /

-0.045 (-0.18%)

MAC Macerich
$8.97 /

+0.195 (+2.22%)

WPG Washington Prime
$0.84 /

+ (+0.00%)

VAL Valaris
$0.65 /

-0.0538 (-7.60%)

SLNO Soleno Therapeutics
$2.21 /

+0.13 (+6.25%)

SKT Tanger Factory
$7.13 /

-0.17 (-2.33%)

MAC Macerich
$8.97 /

+0.195 (+2.22%)

LAKE Lakeland Industries
$22.38 /

+0.54 (+2.47%)

FCEL FuelCell
$2.26 /

-0.07 (-3.00%)

BGS B&G Foods
$24.41 /

-0.045 (-0.18%)

BCLI BrainStorm
$11.20 /

+0.145 (+1.31%)

Over a week ago
Options
Largest borrow rate increases among liquid names » 08:45
06/24/20
06/24
08:45
06/24/20
08:45
NKLA

Nikola

$75.08 /

+5.1 (+7.29%)

, ACB

Aurora Cannabis

$13.58 /

-0.12 (-0.88%)

, CLIR

ClearSign Combustion

$1.89 /

-0.12 (-5.97%)

, SRNE

Sorrento Therapeutics

$5.12 /

+0.205 (+4.18%)

, ATNM

Actinium Pharmaceuticals

$0.42 /

-0.017 (-3.91%)

, TXMD

TherapeuticsMD

$1.25 /

+0.05 (+4.18%)

, NEPT

Neptune Wellness

$3.06 /

+0.52 (+20.47%)

, BBBY

Bed Bath & Beyond

$10.23 /

+0.24 (+2.40%)

, CEMI

Chembio Diagnostics

$3.41 /

-0.25 (-6.83%)

, BCLI

BrainStorm

$9.98 /

+0.35 (+3.63%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: (NKLA) 962.76% +4.10, Aurora Cannabis (ACB) 68.78% +2.13, ClearSign Combustion (CLIR) 97.37% +1.79, Sorrento Therapeutics (SRNE) 135.42% +0.91, Actinium Pharmaceuticals (ATNM) 3.47% +0.68, TherapeuticsMD (TXMD) 21.21% +0.64, Neptune Technologies (NEPT) 50.80% +0.53, Bed Bath & Beyond (BBBY) 6.42% +0.47, Chembio Diagnostics (CEMI) 3.39% +0.40, and BrainStorm (BCLI) 11.12% +0.40.

ShowHide Related Items >><<
TXMD TherapeuticsMD
$1.25 /

+0.05 (+4.18%)

SRNE Sorrento Therapeutics
$5.12 /

+0.205 (+4.18%)

NKLA Nikola
$75.08 /

+5.1 (+7.29%)

NEPT Neptune Wellness
$3.06 /

+0.52 (+20.47%)

CLIR ClearSign Combustion
$1.89 /

-0.12 (-5.97%)

CEMI Chembio Diagnostics
$3.41 /

-0.25 (-6.83%)

BCLI BrainStorm
$9.98 /

+0.35 (+3.63%)

BBBY Bed Bath & Beyond
$10.23 /

+0.24 (+2.40%)

ATNM Actinium Pharmaceuticals
$0.42 /

-0.017 (-3.91%)

ACB Aurora Cannabis
$13.58 /

-0.12 (-0.88%)

NKLA Nikola
$75.08 /

+5.1 (+7.29%)

06/22/20
Fly Intel: Top five analyst initiations
06/22/20 JPMorgan
CNH Industrial price target raised to $8 from $6.50 at JPMorgan
06/22/20 JPMorgan
JPMorgan starts 'fully valued' Nikola with Neutral, $45 price target
06/22/20 JPMorgan
Nikola initiated with a Neutral at JPMorgan
ACB Aurora Cannabis
$13.58 /

-0.12 (-0.88%)

06/24/20 Stifel
Aurora Cannabis upgraded to Hold from Sell at Stifel
05/22/20 CIBC
Aurora Cannabis price target raised to C$24 from C$14 at CIBC
05/22/20
Fly Intel: Top five analyst downgrades
05/22/20 Jefferies
Aurora Cannabis downgraded to Underperform from Hold at Jefferies
CLIR ClearSign Combustion
$1.89 /

-0.12 (-5.97%)

SRNE Sorrento Therapeutics
$5.12 /

+0.205 (+4.18%)

05/26/20 Dawson James
Sorrento Therapeutics initiated with a Buy at Dawson James
10/07/19 JMP Securities
Sorrento Therapeutics initiated with an Outperform at JMP Securities
07/23/19 H.C. Wainwright
Sorrento Therapeutics price target lowered to $30 from $40 at H.C. Wainwright
ATNM Actinium Pharmaceuticals
$0.42 /

-0.017 (-3.91%)

06/04/20 H.C. Wainwright
Actinium Pharmaceuticals initiated with a Buy at H.C. Wainwright
04/17/20 JonesTrading
Key Actinium questions could be answered sooner than expected, says JonesTrading
08/08/19 William Blair
Actinium Pharmaceuticals initiated with an Outperform at William Blair
TXMD TherapeuticsMD
$1.25 /

+0.05 (+4.18%)

05/19/20
Fly Intel: Top five analyst downgrades
05/19/20 JPMorgan
TherapeuticsMD downgraded to Neutral on COVID disruptions at JPMorgan
05/19/20 JPMorgan
TherapeuticsMD downgraded to Neutral from Overweight at JPMorgan
05/07/20 H.C. Wainwright
TherapeuticsMD price target lowered to $5 from $6 at H.C. Wainwright
NEPT Neptune Wellness
$3.06 /

+0.52 (+20.47%)

01/31/20 Cowen
Neptune Wellness initiated with a Market Perform at Cowen
BBBY Bed Bath & Beyond
$10.23 /

+0.24 (+2.40%)

05/26/20 Odeon Capital
Bed Bath & Beyond upgraded to Buy from Hold at Odeon Capital
04/16/20 Loop Capital
Bed Bath & Beyond Q4 results 'less bad than feared' says Loop Capital
04/08/20 Loop Capital
Bed Bath & Beyond price target lowered to $5 from $12 at Loop Capital
03/23/20 Odeon Capital
Bed Bath & Beyond downgraded to Hold from Buy at Odeon Capital
CEMI Chembio Diagnostics
$3.41 /

-0.25 (-6.83%)

06/17/20
Fly Intel: Top five analyst downgrades
06/17/20 Craig-Hallum
Chembio Diagnostics downgraded to Hold from Buy at Craig-Hallum
06/17/20 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
06/17/20 Canaccord
Chembio Diagnostics downgraded to Hold at Canaccord
BCLI BrainStorm
$9.98 /

+0.35 (+3.63%)

TXMD TherapeuticsMD
$1.25 /

+0.05 (+4.18%)

CEMI Chembio Diagnostics
$3.41 /

-0.25 (-6.83%)

BCLI BrainStorm
$9.98 /

+0.35 (+3.63%)

BBBY Bed Bath & Beyond
$10.23 /

+0.24 (+2.40%)

ACB Aurora Cannabis
$13.58 /

-0.12 (-0.88%)

SRNE Sorrento Therapeutics
$5.12 /

+0.205 (+4.18%)

NKLA Nikola
$75.08 /

+5.1 (+7.29%)

BBBY Bed Bath & Beyond
$10.23 /

+0.24 (+2.40%)

ACB Aurora Cannabis
$13.58 /

-0.12 (-0.88%)

TXMD TherapeuticsMD
$1.25 /

+0.05 (+4.18%)

SRNE Sorrento Therapeutics
$5.12 /

+0.205 (+4.18%)

NKLA Nikola
$75.08 /

+5.1 (+7.29%)

NEPT Neptune Wellness
$3.06 /

+0.52 (+20.47%)

CEMI Chembio Diagnostics
$3.41 /

-0.25 (-6.83%)

BBBY Bed Bath & Beyond
$10.23 /

+0.24 (+2.40%)

ACB Aurora Cannabis
$13.58 /

-0.12 (-0.88%)

TXMD TherapeuticsMD
$1.25 /

+0.05 (+4.18%)

SRNE Sorrento Therapeutics
$5.12 /

+0.205 (+4.18%)

NKLA Nikola
$75.08 /

+5.1 (+7.29%)

NEPT Neptune Wellness
$3.06 /

+0.52 (+20.47%)

BBBY Bed Bath & Beyond
$10.23 /

+0.24 (+2.40%)

ACB Aurora Cannabis
$13.58 /

-0.12 (-0.88%)

BBBY Bed Bath & Beyond
$10.23 /

+0.24 (+2.40%)

Hot Stocks
BrainStorm announces new focused on development of NurOwn » 07:06
06/24/20
06/24
07:06
06/24/20
07:06
BCLI

BrainStorm

$9.98 /

+0.35 (+3.63%)

BrainStorm Cell…

BrainStorm Cell Therapeutics announced a new clinical program focused on the development of NurOwn as a treatment for Alzheimer's disease. As part of the newly announced program, the company is planning a multi-national Phase 2 clinical trial to evaluate the safety and efficacy of NurOwn treatment in patients with prodromal to mild Alzheimer's disease.

ShowHide Related Items >><<
BCLI BrainStorm
$9.98 /

+0.35 (+3.63%)

BCLI BrainStorm
$9.98 /

+0.35 (+3.63%)

Hot Stocks
BrainStorm granted SME status by EMA » 09:01
06/15/20
06/15
09:01
06/15/20
09:01
BCLI

BrainStorm

$8.47 /

-0.14 (-1.63%)

BrainStorm Cell…

BrainStorm Cell Therapeutics announced that it has been granted Small and Medium-Sized Enterprise status by the European Medicines Agency's Micro, Small and Medium-Sized Enterprise office. The newly granted SME status allows BrainStorm to participate in significant financial incentives that include a 90% to 100% EMA fee reduction for scientific advice, clinical study protocol design, endpoints and statistical considerations, quality inspections of facilities as well as fee waivers for selective EMA pre and post-authorization regulatory filings, including Orphan Drug and PRIME designations. Brainstorm is also eligible to obtain EMA certification of quality and manufacturing data prior to review of clinical data. Other incentives include EMA-provided translational services of all regulatory documents required for market authorization, further reducing the financial burden of the market authorization process.

ShowHide Related Items >><<
BCLI BrainStorm
$8.47 /

-0.14 (-1.63%)

BCLI BrainStorm
$8.47 /

-0.14 (-1.63%)

Hot Stocks
BrainStorm awarded $500K for ALS biomarker research study by the ALS Association » 06:04
06/09/20
06/09
06:04
06/09/20
06:04
BCLI

BrainStorm

$8.49 /

-0.6 (-6.60%)

The ALS Association and I…

The ALS Association and I AM ALS announced that the organizations have awarded a combined grant of $500,000 to BrainStorm Cell Therapeutics to support an amyotrophic lateral sclerosis, or ALS, biomarker research study. The ALS Association said in a release, "The grant will be used to draw insights from data and samples collected from patients enrolled in BrainStorm's ongoing phase 3 clinical trial of its NurOwn treatment, to further understanding of critical biomarkers associated with treatment response for people with ALS. The study is designed to evaluate how NurOwn interacts with its targets in the brain and spinal cord and to explore the changes in the biomarkers that may correlate with response to the drug treatment. Biomarkers are any measurable substance in the body that change over time, such as cholesterol or blood pressure, and that correlate with disease processes or treatment response. If successful, this study will help confirm that the ALS treatment NurOwn works in the way it is intended and will help inform our larger understanding of ALS biomarkers. The joint award to BrainStorm consists of a $400,000 grant from The ALS Association and a $100,000 grant from I AM ALS. As part of this agreement, BrainStorm has agreed to share data and samples with the ALS community so that the results can be independently validated and to advance other ALS research."

ShowHide Related Items >><<
BCLI BrainStorm
$8.49 /

-0.6 (-6.60%)

BCLI BrainStorm
$8.49 /

-0.6 (-6.60%)

Over a month ago
Hot Stocks
BrainStorm announces NurOwn Phase 3 pivotal trial remains on track » 06:06
06/02/20
06/02
06:06
06/02/20
06:06
BCLI

BrainStorm

$7.65 /

+0.22 (+2.96%)

BrainStorm Cell…

BrainStorm Cell Therapeutics announced an update on the Company's Phase 3 pivotal trial investigating NurOwn in ALS. BrainStorm said in a release, "The Company continues to expect that top-line data from the trial will be announced by Q4-2020, despite the ongoing COVID-19 pandemic that has delayed hundreds of other clinical trials around the world. Due to the importance of the clinical trial and the recognized high unmet need in ALS, Brainstorm and the 6 prestigious U.S. clinical sites have been able to continue treatment visits throughout the COVID-19 pandemic with only occasional scheduling changes to treatments. The decision to continue the trial is also shared by the ALS community and the FDA. The clinical trial sites are at University of California, Irvine; Cedars-Sinai Medical Center; California Pacific Medical Center; Massachusetts General Hospital; University of Massachusetts Medical School and Mayo Clinic. Importantly, the trial's primary outcome measurement is fully validated for telephonic administration, which allowed non-treatment visits to be conducted remotely and to be aligned with protocol assessment timelines. This allows for ongoing high-quality data collection while prioritizing safety of patients and clinical trial site staff."

ShowHide Related Items >><<
BCLI BrainStorm
$7.65 /

+0.22 (+2.96%)

BCLI BrainStorm
$7.65 /

+0.22 (+2.96%)

Earnings
BrainStorm reports Q1 EPS (32c), consensus (22c) » 07:06
05/07/20
05/07
07:06
05/07/20
07:06
BCLI

BrainStorm

$6.78 /

-0.43 (-5.96%)

Cash, cash equivalents,…

Cash, cash equivalents, and short-term bank deposits were approximately $14.5M at March 31, vs. $6.2M at March 31, 2019. "While many companies have been greatly hindered by the COVID-19 pandemic, (...) the Phase 3 ALS trial remains on track for a Q4'20 topline data readout. Participants in the fully enrolled clinical trial in our 6 United States medical centers of excellence continue to receive their scheduled treatments with the necessary safety protocols in place," stated CEO Chaim Lebovits. "We were able to advance our global footprint by signing an agreement with a senior, leading EMEA regulatory consultant who will advise us as we approach EMEA Regulatory Institutions to present data for NurOwn in ALS, and the advancement of NurOwn in other disease indications".

ShowHide Related Items >><<

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.